Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 6/20 | 0.52 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13043811 | 1.00 | CASP3 (0.53) | CASP3CTSKCTSLCTSBCASP1 | |
| SCHEMBL14601914 | 0.93 | CTSK (0.54) | CASP3CTSKCTSLCTSBCASP1 | |
| SCHEMBL13043801 | 0.93 | CTSK (0.54) | CASP3CTSKCTSLCTSBCASP1 | |
| SCHEMBL33525492 | 0.85 | ALDH1A1 (0.50) | CASP3CTSKCTSLCTSBCASP1 | |
| SCHEMBL21111192 | 0.85 | CPB1 (0.49) | CASP3CTSKCTSLCTSBALDH1A1 | |
| SCHEMBL6199732 | 0.84 | CASP3 (0.60) | CASP3CTSKCTSLCTSBCASP1 | |
| SCHEMBL5650545 | 0.83 | CASP3 (0.64) | CASP3CTSKCTSLCTSBCASP1 | |
| SCHEMBL14641301 | 0.83 | CASP3 (0.64) | CASP3CTSKCTSLCTSBCASP1 | |
| SCHEMBL14603133 | 0.83 | CASP3 (0.64) | CASP3CTSKCTSLCTSBCASP1 | |
| SCHEMBL14603128 | 0.83 | CASP3 (0.61) | CASP3CTSKCTSLCASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | CASP3 1380/4885CTSK 280/4885CTSL 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.